Advertisement

Journal of Endocrinological Investigation

, Volume 27, Issue 9, pp 878–882 | Cite as

The early diagnosis of multiple endocrine neoplasia type 1 (MEN 1): A case report

  • G. Tamagno
  • E. De Carlo
  • C. Martini
  • D. Rubello
  • F. Fallo
  • N. Sicolo
Case Report

Abstract

We report the case of a patient presenting amenorrhea, hyperprolactinemia, headache and nuclear magnetic resonance (NMR) evidence of pituitary macroadenoma. The family history revealed that the patient’s father had had a referred sporadic insulinoma, removed 25 yr before without evidence of other endocrine disorders. Physical examination evidenced a slight neck enlargement. Among biochemical and endocrinological assays performed, only hyperprolactinemia was observed. Neck ultrasonography (US) revealed a parathyroid enlargement and a 99mTcO4/MIBI scan showed two hyperplasic lesions. Considering the diagnostic suspect of multiple endocrine neoplasia (MEN1), we performed abdominal US and NMR studies, showing a pancreatic lesion compatible with neuroendocrine tumor. A total body 111In-DTPA-d-Phe1-octreotide scan (Octreoscan®) was also carried out, evidencing no pituitary tumor uptake but high uptake of the abdominal lesion. After surgery, the histological examination confirmed the two parathyroid adenomas and four non-functioning pancreatic neuroendocrine tumors. When the patient was admitted for studying the pituitary lesion and for planning the opportune therapy, an early and partially subclinical stage of MEN1 was identified, potentially already clear but otherwise undiagnosed, and the genetic state of the patient’s relatives, as possible carriers of DNA mutation, was checked. The DNA study for germline mutations confirmed the clinical diagnosis of MEN1 syndrome in the patient and evidenced the same MEN1 mutation in her father and twin sister. In this case report, we would like to underline that, still today, a correct anamnesis and physical examination are the cornerstone of clinical approach to the patient. Furthermore, initial good practice approach is necessary to plan the diagnostic iter, enabling clinicians to decide upon the best orientation and interpretation of the results among several complicated and expensive exams.

Key-words

Multiple endocrine neoplasia MEN1 pituitary adenoma hyperprolactinemia octreoscan nuclear magnetic resonance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Related Cancer 2001, 8: 287–305.CrossRefGoogle Scholar
  2. 2.
    Lubke D, Saeger W. Carcinomas of the pituitary: definition and review of the literature. Gen diagn path 1995, 141: 81–92.Google Scholar
  3. 3.
    Corbetta S, Pizzocaro A, Peracchi M, Beck-Peccoz P, Faglia G, Spada A. Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. Clin Endocrinol (Oxf) 1997, 47: 507–12.CrossRefGoogle Scholar
  4. 4.
    Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Thakker RV. Multipe endocrine neoplasia. Horm Res 2001, 56 (Suppl 1): 67–72.PubMedCrossRefGoogle Scholar
  6. 6.
    Kaczirek K, Prager G, Schindl M, et al. Multiple endocrine neoplasia 1 — Current recommendations for diagnosis and treatment. Wien Klin Wochenschr 2002, 114: 258–66.PubMedGoogle Scholar
  7. 7.
    Marsh D, Zori R. Genetic insights into familial cancers — update and recent discoveries. Cancer Lett 2002, 181: 125–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998, 124: 1106–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002, 87: 457–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Giordano A, Rubello D, Casara D. New trends in parathyroid scintigraphy. Eur J Nucl Med 2001, 28: 1409–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Zarnegar R, Brunaud L, Clark OH. Multiple endocrine neoplasia type I. Curr Treat Options Oncol 2002, 3: 35–48.CrossRefGoogle Scholar
  12. 12.
    Perez-Monte JE, Brown ML, Clarke MR, Watson CG, Carty SE. Parathyroid hyperplasia, thymic carcinoid and pituitary adenoma detected with technetium-99mMIBI in MEN type I. J Nucl Med 1997, 38: 1767–9.PubMedGoogle Scholar
  13. 13.
    Nguyen BD, Wang EA. Multiple endocrine neoplasia type 1: scintigraphic and magnetic resonance demonstration. Clin Nucl Med 1999, 24: 73–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Fidler JL, Johnson CD. Imaging of neuroendocrine tumors of the pancreas. Int J Gastrointest Cancer 2001, 30: 73–85.PubMedCrossRefGoogle Scholar
  15. 15.
    van Eijck CH, Lamberts SW, Lemaire LC, et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 1996, 224: 119–24.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Krausz Y, Bar-Ziv J, de Jong RBJ, et al. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol 1998, 93: 66–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Skogseid B, Öberg K, Äkerström G, et al. Limited tumor involvement found at multiple endocrine neoplasia type 1 pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998, 22: 673–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997, 100: 2386–92.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Jacquet P, Ouafik L, Saveanu A, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 1999, 84: 3268–76.Google Scholar
  20. 20.
    Lamberts SWJ, van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises. Eur J Endocrinol 2002, 146: 701–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Zatelli MD, Piccin D, Franceschetti P, et al. Dopamine-resistant invasive macroprolactinoma: from bench to bedside. J Endocrinol Invest 2002, 25 (Suppl 6): 18 (abstract).Google Scholar
  22. 22.
    Lamberts SWJ, Verleun T, Hofland L, Del Pozo E. A comparison between the effects of SMS201-995, bromocriptine and the combination of both drugs on hormone release by cultured pituitary tumor cells of acromegalic patients. Clin Endocrinol (Oxf) 1987, 27: 11–23.CrossRefGoogle Scholar
  23. 23.
    Wagenaar AH, Harris AG, Van der Lely AJ, Lamberts SWJ. Dynamic of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh) 1991, 125: 637–42.Google Scholar
  24. 24.
    Fredstorp L, Kutz K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open phamacodynamic interaction study. Clin Endocrinol (Oxf) 1994: 41: 103–8.CrossRefGoogle Scholar
  25. 25.
    Flogstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994, 79: 461–5.PubMedGoogle Scholar
  26. 26.
    Abs R, Verhelst J, Master D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83: 374–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Barzon L, Pasquali C, Grigoletto C, Pedrazzoli S, Boscaro M, Fallo F. Multiple Endocrine Neoplasia type 1 and adrenal lesions. J Urol 2001, 166: 24–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Ringe D. Function by serendipity. Nature 2002, 415: 488–9.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2004

Authors and Affiliations

  • G. Tamagno
    • 1
  • E. De Carlo
    • 1
  • C. Martini
    • 1
  • D. Rubello
    • 2
  • F. Fallo
    • 1
  • N. Sicolo
    • 1
  1. 1.Medical Clinic III, Department of Medical and Surgical SciencesUniversity of PadovaPadovaItaly
  2. 2.Nuclear Medicine ServiceS. Maria della Misericordia HospitalRovigoItaly

Personalised recommendations